Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ravidasvir plus sofosbuvir - Drugs for Neglected Diseases initiative/Pharco Pharmaceuticals

Next Previous
Drug Profile

Ravidasvir plus sofosbuvir - Drugs for Neglected Diseases initiative/Pharco Pharmaceuticals

Latest Information Update: 09 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation
  • Class Benzimidazoles; Carbamates; Naphthalenes; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hepatitis C

Most Recent Events

  • 01 Jul 2025 Thailand’s Government Pharmaceutical Organization (GPO), Pharco Pharmaceuticals, and Drugs for Neglected Diseases initiative signed a Memorandum of Understanding (MoU) to support the registration of ravidasvir in Thailand for Heaptitis C
  • 14 Jun 2025 Efficacy and adverse events data from a STORM-C-1 phase II/III trial in Hepatitis C released by Drugs for Neglected Diseases Initiative Foundation
  • 31 Dec 2021 Phase II/III development is ongoing in Thailand and Malaysia (Drugs for Neglected Diseases Initiative pipeline, December 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top